Altamira Therapeutics Ltd., a biopharmaceutical company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on April 10, 2024. The filing is for the purpose of registering an additional 300,000 common shares under the company's Equity Incentive Plan (EIP), as approved by the board of directors on April 3, 2024. These shares are in addition to the shares previously registered for issuance under the EIP in 2019 and 2021. The registration allows for the issuance of common shares to employees as part of their compensation and is a common practice for publicly traded companies to incentivize and retain talent. The documents from previous registrations and recent financial reports have been incorporated by reference into the new Registration Statement, providing a comprehensive overview of the company's financial status and share structure for potential investors and current shareholders.

Altamira Therapeutics Ltd., a biopharmaceutical company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on April 10, 2024. The filing is for the purpose of registering an additional 300,000 common shares under the company's Equity Incentive Plan (EIP), as approved by the board of directors on April 3, 2024. These shares are in addition to the shares previously registered for issuance under the EIP in 2019 and 2021. The registration allows for the issuance of common shares to employees as part of their compensation and is a common practice for publicly traded companies to incentivize and retain talent. The documents from previous registrations and recent financial reports have been incorporated by reference into the new Registration Statement, providing a comprehensive overview of the company's financial status and share structure for potential investors and current shareholders.